SCHEMBL23749577

SCHEMBL23749577

CC1(N)CCN(CCCOc2cc3nccc(Oc4ccc(N)cc4F)c3c3c2OCCO3)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.57
RET P07949 6/20 0.53
KDR P35968 9/20 0.47
MET P08581 3/20 0.46
EGFR P00533 3/20 0.43
RAF1 P04049 3/20 0.43
BRAF P15056 3/20 0.43
PLK4 O00444 1/20 0.43
STK25 O00506 1/20 0.43
CIT O14578 1/20 0.43
AURKA O14965 1/20 0.43
CHUK O15111 1/20 0.43
MUSK O15146 1/20 0.43
EPHB6 O15197 1/20 0.43
MAPK13 O15264 1/20 0.43
MAP3K13 O43283 1/20 0.43
DAPK3 O43293 1/20 0.43
MAP3K7 O43318 1/20 0.43
RIPK2 O43353 1/20 0.43
JAK2 O60674 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23749350 0.94 AXL (0.57) AXLRETKDRMETEGFR
SCHEMBL23749330 0.94 AXL (0.57) AXLRETKDRMETEGFR
SCHEMBL23749340 0.90 AXL (0.60) AXLRETKDRMETEGFR
SCHEMBL31441112 0.90 AXL (0.59) AXLRETKDRMETEGFR
SCHEMBL23749500 0.90 AXL (0.59) AXLRETKDRMETEGFR
SCHEMBL21265307 0.89 AXL (0.68) AXLRETKDRMETEGFR
SCHEMBL23749319 0.89 AXL (0.58) AXLRETKDRMETEGFR
SCHEMBL23749521 0.88 RET (0.55) AXLRETKDRMETEGFR
SCHEMBL23749499 0.86 AXL (0.55) AXLRETKDRMETEGFR
SCHEMBL23749501 0.86 RET (0.56) AXLRETKDRMETEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202835-B2 Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-01-21 US disclosed
US-20220002308-A1 AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2022-01-06 US disclosed
EP-3865487-A1 AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002308-A1 AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF MERTK, AXL, TYRO3 AXL 2/4885RET 4/4885KDR 10/4885
US-12202835-B2 Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors MERTK, AXL, TYRO3 AXL 2/4885RET 4/4885KDR 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.